Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xencor Inc
(NQ:
XNCR
)
16.23
+0.20 (+1.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xencor Inc
< Previous
1
2
3
4
5
6
Next >
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Novartis Dumps Another Bispecific Candidate From Xencor Deal
November 09, 2021
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The...
Via
Benzinga
Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript
November 08, 2021
XNCR earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Xencor: Q3 Earnings Insights
November 08, 2021
Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their...
Via
Benzinga
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
November 08, 2021
From
Xencor, Inc.
Via
Business Wire
Earnings Scheduled For November 8, 2021
November 08, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...
Via
Benzinga
Preview: Xencor's Earnings
November 05, 2021
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
November 04, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
November 03, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
November 02, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
November 01, 2021
From
Xencor, Inc.
Via
Business Wire
JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody
October 04, 2021
Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global...
Via
Benzinga
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
October 04, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
October 01, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021
From
Xencor, Inc.
Via
Business Wire
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Return on Capital Employed Insights for Xencor
August 20, 2021
After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
August 20, 2021
On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-...
Via
Benzinga
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
August 17, 2021
Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater...
Via
Benzinga
Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript
August 04, 2021
XNCR earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Xencor Reports Second Quarter 2021 Financial Results
August 04, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
August 02, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
July 28, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021
From
Xencor, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
August 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Earnings Scheduled For August 4, 2021
August 04, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19
May 26, 2021
From
Xencor, Inc.
Via
Business Wire
Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies
May 25, 2021
Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access...
Via
Benzinga
Exposures
COVID-19
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
May 25, 2021
From
Xencor, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.